Lypo-C CBD from the Liposomal Supplement Brand 'Lypo-C' to Launch Pre-sales for Medical Institutions on June 9th (Mon)

Key facts

  • Lypo-C CBD from the Liposomal Supplement Brand 'Lypo-C' to Launch Pre-sales for Medical Institutions on June 9th (Mon)
  • SPIC Corporation will launch pre-sales of 'Lypo-C CBD,' a liposomal CBD supplement focused on absorption, for medical institutions starting June 9, 2025. Utilizing proprietary Lypo-Capsule technology, it ensures efficient absorption. The product features THC-free broad-spectrum CBD and is recommended by the Clinical CBD Oil Research Association.
  • Source: PR Times
  • Date: May 14, 2025

Direct answer

SPIC Corporation will launch pre-sales of 'Lypo-C CBD,' a liposomal CBD supplement focused on absorption, for medical institutions starting June 9, 2025. Utilizing proprietary Lypo-Capsule technology, it ensures efficient absorption. The product features THC-free broad-spectrum CBD and is recommended by the Clinical CBD Oil Research Association.

Citation
Lypo-C CBD from the Liposomal Supplement Brand 'Lypo-C' to Launch Pre-sales for Medical Institutions on June 9th (Mon) (May 14, 2025), PR Times
Source
PR Times
Date
May 14, 2025
SPIC Corporation will launch pre-sales of 'Lypo-C CBD,' a liposomal CBD supplement focused on absorption, for medical institutions starting June 9, 2025. Utilizing proprietary Lypo-Capsule technology, it ensures efficient absorption. The product features THC-free broad-spectrum CBD and is recommended by the Clinical CBD Oil Research Association.
businessNQ 54/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: May 14, 2025 at 11:00
  • 🔍 Collected: June 1, 2026 at 01:12 (9182h 12m after Published)
  • 🤖 AI Analyzed: June 1, 2026 at 01:14 (1 min after Collected)
SPIC Corporation (Headquarters: Kamakura, Kanagawa; President: Takayuki Shibata), which supports personal health under the mission of 'Creating the Future of Health,' will begin pre-sales of its new product, 'Lypo-C CBD,' for medical institutions on June 9, 2025. CBD has been confirmed safe by international organizations such as the WHO, and with the amendment of the Cannabis Control Act in Japan in December 2024, a legal framework has been established. This marks the beginning of an era where CBD is correctly understood and utilized. SPIC proposes 'Lypo-C CBD,' a medical-grade liposomal supplement focused on absorption and safety. By applying proprietary Lypo-Capsule technology, the CBD is encapsulated in fine liposomes to maximize absorption. It uses broad-spectrum CBD, which contains no THC (<1ppm) and allows multiple cannabinoid components to work gently. Through 'Lypo-C CBD,' we aim to contribute to people's health by delivering 'certain results' and 'correct value,' while pioneering the future of CBD.

FAQ

What is the legal status of CBD in Japan?

Following the amendment of the Cannabis Control Act in December 2024, a legal framework for the proper use of CBD has been established in Japan.

What are the key facts in this article?

SPIC Corporation will launch pre-sales of 'Lypo-C CBD,' a liposomal CBD supplement focused on absorption, for medical institutions starting June 9, 2025. Utilizing proprietary Lypo-Capsule technology, it ensures efficient absorption. The product features THC-free broad-spectrum CBD and is recommended by the Clinical CBD Oil Research Association.

What is the direct answer?

SPIC Corporation will launch pre-sales of 'Lypo-C CBD,' a liposomal CBD supplement focused on absorption, for medical institutions starting June 9, 2025. Utilizing proprietary Lypo-Capsule technology, it ensures efficient absorption. The product features THC-free broad-spectrum CBD and is recommended by the Clinical CBD Oil Research Association.

Back to Newsroom (60)